Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions Journal Article

Local Library Link: Find It @ Loyola

Authors: Kaja, S.; Shah, A. A.; Haji, S. A.; Patel, K. B.; Naumchuk, Y.; Zabaneh, A.; Gerdes, B. C.; Kunjukunju, N.; Sabates, N. R.; Cassell, M. A.; Lord, R. K.; Pikey, K. P.; Poulose, A.; Koulen, P.
Article Title: Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions
Abstract: The main objective of the study was to quantify serum levels of nicotinamide phosphoribosyltransferase (Nampt/pre-B-Cell colony-enhancing factor 1/visfatin) in subjects with a history of retinal vascular occlusions (RVOs), disease conditions characterized by pronounced ischemia, and metabolic energy deficits. A case-control study of 18 subjects with a history of RVO as well as six healthy volunteers is presented. Serum Nampt levels were quantified using a commercially available enzyme-linked immunosorbent assay kit. Serum Nampt levels were 79% lower in patients with a history of RVO compared with that in healthy volunteers (P0.05). There was no statistically significant difference among the types of RVOs, specifically branch retinal vein occlusions (n=7), central retinal vein occlusions (n=5), hemiretinal vein occlusions (n=3), and central retinal artery occlusions (n=3; P=0.69). Further studies are needed to establish the temporal kinetics of Nampt expression and to determine whether Nampt may represent a novel biomarker to identify at-risk populations, or whether it is a druggable target with the potential to ameliorate the long-term complications associated with the condition, ie, macular edema, macular ischemia, neovascularization, and permanent loss of vision.
Journal Title: Clinical ophthalmology (Auckland, N.Z.)
Volume: 9
ISSN: 1177-5467; 1177-5467
Publisher: Unknown  
Journal Place: New Zealand
Date Published: 2015
Start Page: 611
End Page: 618
Language: ENG
DOI/URL:

10.2147/OPTH.S80784
Notes: LR: 20161019; GR: P01 AG022550/AG/NIA NIH HHS/United States; GR: P01 AG027956/AG/NIA NIH HHS/United States; GR: R01 EY014227/EY/NEI NIH HHS/United States; GR: P01 AG010485/AG/NIA NIH HHS/United States; GR: R01 EY022774/EY/NEI NIH HHS/United States; GR: S10 RR027093/RR/NCRR NIH HHS/United States; GR: S10 RR022570/RR/NCRR NIH HHS/United States; JID: 101321512; OID: NLM: PMC4396426; OTO: NOTNLM; epublish
LUC Authors
  1. Simon Kaja
    39 Kaja
Related LUC Article